Le. Mather et al., PHARMACOKINETICS OF BUPIVACAINE ENANTIOMERS IN SHEEP - INFLUENCE OF DOSAGE REGIMEN AND STUDY DESIGN, Journal of pharmacokinetics and biopharmaceutics, 22(6), 1994, pp. 481-498
Bupivacaine is used as a racemate. In previous studies the mean total
body clearance of R(+)-bupivacaine was found to be greater than S(-)-b
upivacaine by 65% after iv bolus dose of separate enantiomers and by 2
0% after iv infusion to steady state of racemate. The present studies
were performed to determine whether different study designs using diff
erent iv dosage regimens could influence the pharmacokinetic parameter
s determined for either bupivacaine enantiomer. rac-Bupivacaine . HCl
was administered iv to 6 adult Merino ewes by bolus, brief infusion, a
nd prolonged infusion. Arterial blood concentrations of R(+)- and S(-)
-bupivacaine were measured by enantioselective HPLC. These regimens co
nsistently produced lower arterial blood concentrations of R(+)-bupiva
caine than S(-)-bupivacaine due to R(+)-bupivacaine having a greater i
nitial dilution volume by 16 (95% CI = 3-29) %, volume of distribution
at steady state equilibrium by 32 (95% CI=17-32)% and mean total body
clearance by 28 (95% CI=21-35). The slow half-life of R(+)-bupivacain
e, however, was found to be 15 (95% CI=0-31)% longer than that of S(-)
-bupivacaine. The difference between enantiomers in mean total body cl
earance thus was similar to tire previous study based upon infusion to
steady state of rac-bupivacaine. Differences in pharmacokinetics attr
ibutable to the dosage regimen consisted of a greater mean total body
clearance for R(+)-bupivacaine along with a smaller terminal half life
with the bolus regimen and a longer half-life of S(-)-bupivacaine aft
er prolonged infusion. Differences in pharmacokinetics between the bup
ivacaine enantiomers occurred consistently in both distribution and cl
earance but the magnitude of the effect was less than 50% in each case
. Systematic differences in pharmacokinetics associated with the dosag
e regimen were found mainly in terminal half-life. Dosage regimen, thu
s, was found to influence the pharmacokinetic results found experiment
ally and is therefore a significant variable in its own right.